Get the Stockscreener App
90.80
0.36%
0.33
After Hours:
90.80
Globus Medical Inc stock is traded at $90.80, with a volume of 1.83M.
It is up +0.36% in the last 24 hours and up +8.85% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
See More
Previous Close:
$90.47
Open:
$90.62
24h Volume:
1.83M
Relative Volume:
1.85
Market Cap:
$12.36B
Revenue:
$2.48B
Net Income/Loss:
$91.51M
P/E Ratio:
135.52
EPS:
0.67
Net Cash Flow:
$293.77M
1W Performance:
+4.28%
1M Performance:
+8.85%
6M Performance:
+24.71%
1Y Performance:
+65.33%
1-Day Range:
$89.34
$91.04
1-Week Range:
$86.28
$91.44
52-Week Range:
$49.33
$91.44
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
90.80 | 12.36B | 2.48B | 91.51M | 293.77M | 0.67 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Here's Why Globus Medical (GMED) is a Strong Growth Stock - Yahoo Finance
Globus Medical (STU:GM0N) Earnings Yield % : 0.70% (As of Jan. 19, 2025) - GuruFocus.com
Oak Thistle LLC Acquires New Shares in Globus Medical, Inc. (NYSE:GMED) - MarketBeat
Globus Medical (NYSE:GMED) Sets New 1-Year HighWhat's Next? - MarketBeat
Globus Medical, Inc. (NYSE:GMED) Shares Sold by Covea Finance - MarketBeat
Kathmere Capital Management LLC Buys New Position in Globus Medical, Inc. (NYSE:GMED) - MarketBeat
Globus Medical Reports Robust Q3 2024 Financial Performance and Raises Annual Outlook - MSN
Globus medical COO Keith Pfeil sells $1.25 million in stock By Investing.com - Investing.com Canada
Globus medical COO Keith Pfeil sells $1.25 million in stock - Investing.com India
Keith W. Pfeil Sells 14,167 Shares of Globus Medical, Inc. (NYSE:GMED) Stock - MarketBeat
FY2024 EPS Estimates for Globus Medical Increased by Analyst - MarketBeat
Brokerages Set Globus Medical, Inc. (NYSE:GMED) Price Target at $96.91 - MarketBeat
Globus Medical (STU:GM0N) Capex-to-Operating-Cash-Flow : 0.21 (As of Sep. 2024) - GuruFocus.com
Globus Medical Reports Record Sales Growth for 2024 - MSN
Globus Medical anticipates Q4 sales of $657 million - MSN
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues - MSN
Canaccord Genuity Group Forecasts Strong Price Appreciation for Globus Medical (NYSE:GMED) Stock - MarketBeat
Globus Medical stock soars to all-time high of $88.67 - Investing.com
Globus Medical upgraded to Neutral from Underperform at BofA - Yahoo Finance
Globus Medical (MEX:GMED) Net Income : MXN1,740 Mil (TTM As of Sep. 2024) - GuruFocus.com
Globus Medical (MEX:GMED) EPS without NRI : MXN44.05 (TTM As of Sep. 2024) - GuruFocus.com
Globus Medical, Inc.'s (NYSE:GMED) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Simply Wall St
B of A Securities Upgrades Globus Medical (GMED) - MSN
Truist maintains hold on Globus Medical, keeps $90 target By Investing.com - Investing.com Canada
Globus Medical upgraded to neutral by BoA on Q4 performance - MSN
Globus Medical stock upgraded to Neutral after better-than-expected NuVasive integration - Investing.com Canada
Globus Medical (NYSE:GMED) Stock Rating Upgraded by Bank of America - MarketBeat
Globus Medical (NYSE:GMED) Receives Hold Rating from Needham & Company LLC - MarketBeat
Globus Medical, Inc. (NYSE:GMED) Shares Sold by Diversified Trust Co - MarketBeat
Globus Medical reports increased sales, optimistic 2025 outlook By Investing.com - Investing.com Australia
Globus Medical, Inc. Provides Sales Results for the Fourth Quarter and Full Year Ended December 31, 2024 and Provides Earnings Guidance for the Full Year Fiscal 2025 - Marketscreener.com
Globus Medical (NYSE:GMED) Updates FY 2025 Earnings Guidance - MarketBeat
Globus Medical reports increased sales, optimistic 2025 outlook - Investing.com
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results - The Manila Times
Globus Medical Reports Strong 60.6% Sales Growth, Sets Ambitious $2.69B Revenue Target for 2025 - StockTitan
Globus Medical (NYSE:GMED) Trading Up 3%Here's What Happened - MarketBeat
The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors - Business Wire
Confocal Microscopy Market Expected to Expand at a Steady from - openPR
Globus Medical Stock Revs Up For Next Move After 70% Run - MSN
Price Over Earnings Overview: Globus Medical - Benzinga
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term - MSN
Globus Medical, Inc. (NYSE:GMED) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Globus Medical gets FDA approval for two knee replacement products - MSN
Principal Financial Group Inc. Decreases Stake in Globus Medical, Inc. (NYSE:GMED) - MarketBeat
Franklin Resources Inc. Takes Position in Globus Medical, Inc. (NYSE:GMED) - MarketBeat
Reasons to Add GMED Stock to Your Portfolio Right Now - MSN
Globus Medical: Strong Q3 Sales and Product Intros - https://ryortho.com/
This Globus Medical Insider Reduced Their Stake By 100% - Simply Wall St
Roth Capital Raises Earnings Estimates for Globus Medical - MarketBeat
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):